# Qpex Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qpex-biopharma

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.qpexbio.com
- Total disclosed funding: $33M
- Latest round: Series A (Oct 16, 2018)
- Investors on record: 6

## About

Qpex Biopharma, Inc., based in the US, specializes in the research and development of innovative therapies targeting antimicrobial resistance, offering solutions to combat critical global health challenges.Founded in 2018 and headquartered in San Diego, US, Qpex Biopharma, Inc. develops anti-infectives aimed at treating infections caused by resistant pathogens. The company has undergone no significant pivots in its strategy and operates independently, without subsidiaries. Led by founder and CEO Michael Dudley, who has a history of leadership in biopharmaceutical ventures, Qpex has successfully raised a total of USD 100.00 mn across 2 deals, with a most recent deal on June 25, 2023, involving a TRADE SALE for USD 100.00 mn.Qpex Biopharma focuses on developing innovative therapies to combat antimicrobial resistance (AMR), addressing a critical global health threat. The company’s core product offerings include a pipeline of clinically proven anti-infectives, which are designed to target specific bacterial and fungal pathogens exhibiting resistance. These novel therapies are aimed at improving patient outcomes and enhancing the effectiveness of treatment options available to healthcare providers. Qpex's products are primarily targeted towards healthcare institutions, including hospitals and outpatient facilities, where infections caused by resistant pathogens pose significant challenges to patient care. The geographical markets for these products include the United States and other regions facing rising instances of AMR, highlighting the company's commitment to addressing health crises on a global scale.Qpex Biopharma generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on the delivery of its anti-infective therapies. The structure of transactions typically involves licensing agreements, where Qpex provides its proprietary technologies and drug formulations to partners in exchange for royalties or milestone payments based on development and sales performance. The company’s flagship products, including novel combinations like Xeruborbactam with Cefiderocol, are integral to its revenue model, aimed at addressing the urgent need for new antibiotics. These transactions are conducted directly with healthcare providers and through strategic partnerships, ensuring that Qpex's innovative solutions reach the end-users effectively while contributing to the company's financial stability and growth.In June 2023, Qpex Biopharma entered into a TRADE SALE agreement with SHIONOGI & CO., LTD. for USD 140 mn, including USD 100 mn upfront and an additional USD 40 mn contingent upon achieving certain milestones. This transaction, expected to close by July 2023, will enhance Qpex's capabilities in drug and treatment development for infectious diseases. The funding will support the acceleration of new product pipelines and expansion into new geographic markets, specifically targeting areas with high levels of antimicrobial resistance.

## Funding rounds

- Series A, Oct 16, 2018, $33M — Adams Street Partners, New Enterprise Associates, Hatteras Venture Partners, Stanford University, Biomedical Advanced Research and Development Authority, LYZZ Capital

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Stanford University — Series A
- Biomedical Advanced Research and Development Authority — Series A
- LYZZ Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series A